CADL Candel Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CADL

Price (delayed)

$9.265

Market cap

$678.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.99

Enterprise value

$532.87M

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3
Highlights
Candel Therapeutics's equity has surged by 166% QoQ and by 85% YoY
CADL's quick ratio has surged by 107% since the previous quarter
Candel Therapeutics's EPS has decreased by 38% QoQ but it has increased by 24% YoY
The net income has declined by 43% since the previous quarter and by 38% year-on-year
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CADL

CADL stock price

How has the Candel Therapeutics stock price performed over time
Intraday
5.28%
1 week
14.52%
1 month
23.04%
1 year
65.45%
YTD
63.98%
QTD
89.08%

Financial performance

How have Candel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.42M
Net income
-$54.42M
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 68% YoY and by 17% QoQ
The net income has declined by 43% since the previous quarter and by 38% year-on-year

Price vs fundamentals

How does CADL's price correlate with its fundamentals

Growth

What is Candel Therapeutics's growth rate over time

Valuation

What is Candel Therapeutics stock price valuation
P/E
N/A
P/B
4.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Candel Therapeutics's EPS has decreased by 38% QoQ but it has increased by 24% YoY
Candel Therapeutics's equity has surged by 166% QoQ and by 85% YoY
The P/B is 51% above the 5-year quarterly average of 3.1 and 26% above the last 4 quarters average of 3.7

Efficiency

How efficient is Candel Therapeutics business performance
Candel Therapeutics's ROE has soared by 56% YoY but it has decreased by 18% from the previous quarter
The company's return on invested capital rose by 40% QoQ
CADL's ROA is up by 35% YoY but it is down by 14% from the previous quarter

Dividends

What is CADL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CADL.

Financial health

How did Candel Therapeutics financials performed over time
The total assets has soared by 111% year-on-year and by 61% since the previous quarter
The current ratio has soared by 108% from the previous quarter
Candel Therapeutics's debt is 64% lower than its equity
Candel Therapeutics's equity has surged by 166% QoQ and by 85% YoY
CADL's debt to equity has surged by 140% year-on-year but it has dropped by 62% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.